A Multisite Retrospective Review of Direct Oral Anticoagulants Compared to Warfarin in Adult Fontan Patients

[1]  K. Dimopoulos,et al.  Systematic Review Non-Vitamin K Oral Anticoagulants in Adults with Congenital Heart Disease. , 2020, Journal of clinical medicine.

[2]  K. Dimopoulos,et al.  Non-Vitamin K Oral Anticoagulants in Adults with Congenital Heart Disease: A Systematic Review , 2020, Journal of Clinical Medicine.

[3]  A. Niesert,et al.  Direct oral anticoagulants in adults with congenital heart disease - a single centre study. , 2020, International journal of cardiology.

[4]  M. Schwerzmann,et al.  Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study. , 2020, International journal of cardiology.

[5]  M. Schwerzmann,et al.  Non-vitamin K antagonist oral anticoagulants in adults with a Fontan circulation: are they safe , 2019, Open Heart.

[6]  Stephanie Fuller,et al.  2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Circulation.

[7]  Stephanie Fuller,et al.  2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[8]  Emily C. O'Brien,et al.  Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation , 2018, Circulation.

[9]  P. Ermis,et al.  Novel oral anticoagulant use in adult Fontan patients: A single center experience , 2018, Congenital heart disease.

[10]  B. Mulder,et al.  Is Initiating NOACs for Atrial Arrhythmias Safe in Adults with Congenital Heart Disease? , 2017, Cardiovascular Drugs and Therapy.

[11]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[12]  D. Driscoll,et al.  Thrombotic and Embolic Complications Associated With Atrial Arrhythmia After Fontan Operation: Role of Prophylactic Therapy. , 2016, Journal of the American College of Cardiology.

[13]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[14]  A. Niesert,et al.  Usefulness of Direct Oral Anticoagulants in Adult Congenital Heart Disease. , 2016, The American journal of cardiology.

[15]  K. Cheng,et al.  The Use of Novel Oral Anticoagulants in Adult Congenital Heart Disease: A Single Center Experience. , 2016, The American journal of cardiology.

[16]  G. V. Van Hare,et al.  Reply to the Editor--Concern regarding adult congenital heart disease arrhythmia guidelines. , 2015, Heart rhythm.

[17]  Bennett P. Samuel,et al.  Thrombosis in Fontan patient on apixaban. , 2015, International journal of cardiology.

[18]  John K. Triedman,et al.  PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: Executive Summary , 2014 .

[19]  P. Podolec,et al.  Abnormalities in blood coagulation, fibrinolysis, and platelet activation in adult patients after the Fontan procedure. , 2014, The Journal of thoracic and cardiovascular surgery.

[20]  A. Agarwal,et al.  Thrombosis and Thromboembolic Complications in Fontan Patients , 2014, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[21]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[22]  J. Mayer,et al.  Effect of aspirin and warfarin therapy on thromboembolic events in patients with univentricular hearts and Fontan palliation. , 2013, International journal of cardiology.

[23]  D. Atar,et al.  Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trial , 2013 .

[24]  B. McCrindle,et al.  Factors associated with thrombotic complications after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary thromboprophylaxis for 2 years after the Fontan procedure. , 2013, Journal of the American College of Cardiology.

[25]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[26]  B. Gersh,et al.  Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. , 2010, American heart journal.

[27]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[28]  M. Jacobs,et al.  Thromboembolism and the Role of Anticoagulation in the Fontan Patient , 2007, Pediatric Cardiology.

[29]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[30]  P. Hanrath,et al.  Thromboembolic complications after Fontan procedures: comparison of different therapeutic approaches. , 2002, The Annals of thoracic surgery.

[31]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[32]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[33]  F. Piscione,et al.  Antiplatelet Versus Anticoagulation Therapy After Extracardiac Conduit Fontan: A Systematic Review and Meta-Analysis , 2010, Pediatric Cardiology.